美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Valion Bio Inc

1.68

-0.4600-21.50%

盘后：1.730.0500+2.98%18:02 EDT

成交量：24.91万

成交额：44.69万

市值：327.23万

市盈率：-0.01

高：2.14

开：2.10

低：1.59

收：2.14

52周最高：76.50

52周最低：1.59

股本：194.78万

流通股本：194.49万

量比：1.45

换手率：12.81%

股息：- -

股息率：- -

每股收益(TTM):-210.1984

每股收益(LYR):-192.0762

净资产收益率：-459.52%

总资产收益率：-57.13%

市净率：0.77

市盈率(LYR):-0.01

数据加载中...

总览公司新闻资讯公告

Valion Bio Inc宣布高层任命：Lisa Wolf出任总裁兼首席运营官，并继续兼任首席财务官

Valion Bio突发人事变动：CEO Michael K. Handley被解职，8月16日正式生效

乌克兰卫生部依据监管等效路径正式受理Entolimod档案进行审评

Afrri/Niaid 设计专有PBI-BM2.5方案，评估Valion Bio（纳斯达克：VBIO）的Entolimod作为首个且唯一GI-ARS疗法

Valion Bio获美国国家过敏和传染病研究所首项FDA先例研究方案用于Entolimod™；联邦机构将全额资助BLA启动物体内研究计划并共同推进FDA申报

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/VBIO/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VBIO\",,,,,undefined,":{"symbol":"VBIO","market":"US","secType":"STK","nameCN":"Valion Bio Inc","latestPrice":1.68,"timestamp":1791835200000,"preClose":2.14,"halted":0,"volume":249115,"hourTrading":{"tag":"盘后","latestPrice":1.73,"preClose":1.68,"latestTime":"18:02 EDT","volume":8331,"amount":14806.5296772,"timestamp":1791842572813,"change":0.05,"changeRate":0.029762,"amplitude":0.279762},"delay":0,"changeRate":-0.21495327102803746,"floatShares":1944864,"shares":1947800,"eps":-210.1984,"marketStatus":"盘后交易","change":-0.46,"latestTime":"10-12 18:19:05 EDT","open":2.1,"high":2.14,"low":1.59,"amount":446893.277614,"amplitude":0.257009,"askPrice":1.8,"askSize":1000,"bidPrice":1.54,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-210.1984,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1791849600000},"marketStatusCode":4,"adr":0,"listingDate":1636606800000,"exchange":"NASDAQ","adjPreClose":2.14,"preHourTrading":{"tag":"盘前","latestPrice":2.1,"preClose":2.14,"latestTime":"09:25 EDT","volume":1871,"amount":3868.4341347,"timestamp":1791811520072,"change":-0.04,"changeRate":-0.018692,"amplitude":0.082196},"postHourTrading":{"tag":"盘后","latestPrice":1.73,"preClose":1.68,"latestTime":"18:02 EDT","volume":8331,"amount":14806.5296772,"timestamp":1791842572813,"change":0.05,"changeRate":0.029762,"amplitude":0.279762},"volumeRatio":1.446239},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VBIO\",,,,,undefined,":{"symbol":"VBIO","floatShares":1944864,"roa":"-57.13%","roe":"-459.52%","lyrEps":-192.076175,"volumeRatio":1.446239,"shares":1947800,"dividePrice":0,"high":2.14,"amplitude":0.257009,"preClose":2.14,"low":1.59,"week52Low":1.59,"pbRate":"0.77","psRate":"-38.05","week52High":76.5,"institutionHeld":0,"latestPrice":1.68,"committee":-0.818182,"eps":-210.1984,"divideRate":0,"volume":249115,"delay":0,"ttmEps":-210.1984,"open":2.1,"prevYearClose":36.25,"prevWeekClose":2.14,"prevMonthClose":2.8,"prevQuarterClose":2.8,"fiveDayClose":2.48,"twentyDayClose":2.1,"sixtyDayClose":12.625},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VBIO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-31","symbol":"VBIO","defaultRemindTime":1788183000000,"type":"split","dateTimestamp":1788148800000,"forFactor":25,"toFactor":1,"ratio":25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VBIO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VBIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VBIO","date":"2026-10-09","current":-0.007992,"percent":0.738739,"low":-0.392475,"twenty":-0.184551,"median":-0.126472,"eighty":-0.087792,"high":-0.027033,"avg":-0.145065,"sd":0.079435,"marketCap":1961571},"quantilePoints":[{"date":"2026-04-30","current":-0.311197,"twenty":-0.324163,"median":-0.319301,"eighty":-0.314439,"marketCap":2762808},{"date":"2026-05-08","current":-0.33713,"twenty":-0.336482,"median":-0.327405,"eighty":-0.314439,"marketCap":2993043},{"date":"2026-05-15","current":-0.329149,"twenty":-0.341701,"median":-0.33551,"eighty":-0.327405,"marketCap":2922183},{"date":"2026-05-22","current":-0.203146,"twenty":-0.339301,"median":-0.327405,"eighty":-0.203206,"marketCap":2758322},{"date":"2026-05-29","current":-0.18116,"twenty":-0.338751,"median":-0.311197,"eighty":-0.201597,"marketCap":2459794},{"date":"2026-06-05","current":-0.173392,"twenty":-0.33713,"median":-0.203331,"eighty":-0.18116,"marketCap":2354321},{"date":"2026-06-12","current":-0.138668,"twenty":-0.333889,"median":-0.20236,"eighty":-0.175704,"marketCap":1882829},{"date":"2026-06-18","current":-0.131547,"twenty":-0.330097,"median":-0.198754,"eighty":-0.158647,"marketCap":1786145},{"date":"2026-06-26","current":-0.136114,"twenty":-0.327754,"median":-0.18598,"eighty":-0.135201,"marketCap":1848155},{"date":"2026-07-02","current":-0.122229,"twenty":-0.327405,"median":-0.179125,"eighty":-0.130362,"marketCap":1659627},{"date":"2026-07-10","current":-0.117868,"twenty":-0.31768,"median":-0.175704,"eighty":-0.126637,"marketCap":1600412},{"date":"2026-07-17","current":-0.115133,"twenty":-0.303417,"median":-0.165705,"eighty":-0.121795,"marketCap":1563282},{"date":"2026-07-24","current":-0.06742,"twenty":-0.241361,"median":-0.149117,"eighty":-0.119839,"marketCap":915435},{"date":"2026-07-31","current":-0.065535,"twenty":-0.203355,"median":-0.136114,"eighty":-0.117713,"marketCap":889829},{"date":"2026-08-07","current":-0.064804,"twenty":-0.203188,"median":-0.130843,"eighty":-0.108033,"marketCap":879906},{"date":"2026-08-14","current":-0.040264,"twenty":-0.202832,"median":-0.129351,"eighty":-0.073786,"marketCap":546700},{"date":"2026-08-21","current":-0.027033,"twenty":-0.202055,"median":-0.126472,"eighty":-0.068316,"marketCap":506868},{"date":"2026-08-28","current":-0.145091,"twenty":-0.20046,"median":-0.129351,"eighty":-0.070603,"marketCap":2720462},{"date":"2026-09-04","current":-0.132547,"twenty":-0.198079,"median":-0.130843,"eighty":-0.073078,"marketCap":2485249},{"date":"2026-09-11","current":-0.104144,"twenty":-0.196943,"median":-0.130244,"eighty":-0.073125,"marketCap":1952695},{"date":"2026-09-18","current":-0.105564,"twenty":-0.194796,"median":-0.129235,"eighty":-0.07355,"marketCap":1979323},{"date":"2026-09-25","current":-0.164736,"twenty":-0.188071,"median":-0.128265,"eighty":-0.075261,"marketCap":3088809},{"date":"2026-10-02","current":-0.118819,"twenty":-0.187068,"median":-0.129233,"eighty":-0.079693,"marketCap":2227848},{"date":"2026-10-09","current":-0.104617,"twenty":-0.184551,"median":-0.126472,"eighty":-0.087792,"marketCap":1961571}],"updateTime":1791843545846},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VBIO\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1152230727","title":"Valion Bio Inc宣布高层任命：Lisa Wolf出任总裁兼首席运营官，并继续兼任首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1152230727","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152230727?lang=zh_cn&edition=fundamental","pubTime":"2026-09-01 20:12","pubTimestamp":1788264748,"startTime":"0","endTime":"0","summary":"Valion Bio Inc（VBIO）今日发布重要人事任命公告。据悉，Lisa Wolf已正式被委任为公司总裁兼首席运营官（President & Chief Operating Officer）。值得注意的是，在履新上述职务的同时，她还将继续肩负首席财务官（CFO）的重任。此番人事调整，标志着公司管理层架构迎来关键性变动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135704668","title":"Valion Bio突发人事变动：CEO Michael K. Handley被解职，8月16日正式生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1135704668","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135704668?lang=zh_cn&edition=fundamental","pubTime":"2026-08-17 18:13","pubTimestamp":1786961590,"startTime":"0","endTime":"0","summary":"据美国证券交易委员会最新披露的文件显示，Valion Bio公司首席执行官Michael K. Handley已被终止职务，该决定将于今年8月16日正式生效。作为一家生物科技企业，Valion Bio在业内一直备受关注，而此番高层变动无疑为公司的未来走向增添了新的不确定性。不过，截至目前，公司方面尚未就此次人事变动的具体原因作出进一步说明。Valion Bio接下来如何平稳过渡、谁将接任这一关键职位，都将成为市场关注的焦点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VBIO","BK4082","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108799602","title":"乌克兰卫生部依据监管等效路径正式受理Entolimod档案进行审评","url":"https://stock-news.laohu8.com/highlight/detail?id=1108799602","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108799602?lang=zh_cn&edition=fundamental","pubTime":"2026-07-22 19:46","pubTimestamp":1784720777,"startTime":"0","endTime":"0","summary":"乌克兰卫生部已正式接受Entolimod（一种用于治疗急性辐射综合征的候选药物）的注册档案，并依据其监管等效性路径启动正式审评程序。此举标志着该药物在乌克兰的监管审批进程迈出了关键一步。\nEntolimod由Valion Bio Inc开发，此次档案受理意味着该药物在乌克兰的上市申请已进入实质性审查阶段。监管等效性路径允许乌克兰主管部门参考其他严格监管机构（如美国FDA或欧洲EMA）的审评数据与决策，以加速本国审批流程。\n这一进展为Entolimod未来在乌克兰市场的潜在获批奠定了基础，也为Valion Bio Inc拓展其全球布局提供了新的监管机遇。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VBIO","BK4139","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161118562","title":"Afrri/Niaid 设计专有PBI-BM2.5方案，评估Valion Bio（纳斯达克：VBIO）的Entolimod作为首个且唯一GI-ARS疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1161118562","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161118562?lang=zh_cn&edition=fundamental","pubTime":"2026-06-25 19:46","pubTimestamp":1782387982,"startTime":"0","endTime":"0","summary":"美国陆军放射生物学研究所与国立过敏和传染病研究所联合设计了一项专有的PBI-BM2.5研究方案，旨在评估Valion Bio Inc（纳斯达克股票代码：VBIO）旗下药物Entolimod，将其作为首个也是目前唯一用于治疗胃肠道急性辐射综合征的候选疗法。这项专门设计的方案旨在验证该药物的有效性与安全性，标志着针对这一严重辐射损伤的治疗开发迈出了关键一步。若最终评估结果积极，Entolimod有望填补该治疗领域长期存在的空白，为受辐射影响的胃肠道系统提供首个靶向治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VBIO","BK4139","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120053939","title":"Valion Bio获美国国家过敏和传染病研究所首项FDA先例研究方案 用于Entolimod™；联邦机构将全额资助BLA启动物体内研究计划并共同推进FDA申报","url":"https://stock-news.laohu8.com/highlight/detail?id=1120053939","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120053939?lang=zh_cn&edition=fundamental","pubTime":"2026-05-05 20:01","pubTimestamp":1777982492,"startTime":"0","endTime":"0","summary":"Valion Bio公司宣布，已从美国国家过敏和传染病研究所获得针对Entolimod™的首个FDA先例研究方案。这一重要进展标志着联邦机构将全面资助该公司开展生物制品许可申请相关的动物体内研究项目，并将协同推进FDA申报流程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VBIO","BK4082"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}